Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search
 

Family History

Population-based estimates of the prevalence of family history of cancer among women
Ingrid J. Hall1, Wylie Burke2, Steven Coughlin1, and Nancy C. Lee1

line

Tables

back to report

TABLE 1: Prevalence of family history of cancer among female relatives of controls
in the Cancer and Steroid Hormone study (CASH), 1980-1982, N=4530

Cancer

n
Prevalence (%) a
95% CL
Breast First-degree
290
6.4
5.7, 7.1
Second-degree
602
13.3
12.3, 14.3
None
3593
79.3
78.1, 80.5
Unknown b
45
1.0
0.7, 1.3
Ovary First-degree
50
1.1
0.8, 1.4
Second-degree
65
1.4
1.1, 1.7
None
4363
96.3
95.8, 96.8
Unknown b
52
1.2
0.8, 1.4
Endometrium First-degree
158
3.5
3.0, 4.0
Second-degree
119
2.6
2.1, 3.1
None
4204
92.8
92.0, 93.6
Unknown b
49
1.1
0.8, 1.4
Cervix c First-degree
96
2.1
1.7, 2.5
None
4370
96.5
96.0, 97.0
Unknown b
42
0.9
0.6, 1.2
Colorectal c First-degree
110
2.4
2.1, 2.9
None
4279
94.5
93.8, 95.2
Unknown b
48
1.1
0.8, 1.4
Lung c First-degree
69
1.5
1.2, 1.8
None
4390
96.9
93.4, 97.4
Unknown b
47
1.0
0.7, 1.3
Thyroid c First-degree
22
0.5
0.3, 0.7
None
4455
98.3
97.9, 98.7
Unknown b
49
1.1
0.8, 1.4
Other c First-degree
406
9.0
8.2, 9.8
None
3778
83.4
82.3, 84.5
Unknown b
33
0.7
0.5, 0.9

a May not total 100% due to incomplete information on second-degree relatives.
b Respondent did not know if her first-degree relatives had this cancer type.
c Second-degree prevalence not reported due to incomplete information on aunts.

back to report


TABLE 2: Prevalence of family history of cancer among female relatives by age of respondents, 
Cancer and Steroid Hormone (CASH) study, 1980-1982, N=4262 a

 
Age Group (years) 
30 - 39 (n=980) 40 - 49 (n=1927) 50 - 54 (n=1355)
n
Prev (%) b
95 % CL
n
Prev (%) a
95 % CL
n
Prev (%) b
95 % CL
Breast
42
4.3
3.0, 5.6
133
6.9
5.8, 8.0
112
8.3 ***
6.8, 9.8
2 °
145
14.8
12.6, 17.0
261
13.5
12.0, 15.0
165
12.2
10.5, 13.9
None
790
80.6
78.1, 83.1
1513
78.5
76.7, 80.3
1056
77.9
75.7, 80.1
Unk c
3
0.3
0, 0.6
20
1.0
0.6, 1.4
22
1.6 **
0.9, 2.3
Ovary
9
0.9
0.3, 1.5
20
1.0
0.6, 1.4
17
1.3
0.7, 1.9
2 °
16
1.6
0.8, 2.4
29
1.5
1.0, 2.0
18
1.3
0.7, 1.9
None
951
97.0
95.9, 98.1
1855
96.3
95.5, 97.1
1295
95.6
94.5, 96.7
Unk c
4
0.4
0, 0.8
23
1.2
0.7, 1.7
25
1.9 *
1.2, 2.6
Endometrium
26
2.7
1.7, 3.7
77
4.0
3.1, 4.9
52
3.8
2.8, 4.8
2 °
28
2.9
1.8, 4.0
49
2.5
1.8, 3.2
35
2.6
1.8, 3.4
None
922
94.1
92.6, 95.6
1782
92.5
91.3, 93.7
1242
91.7
96.2, 93.2
Unk c
4
0.4
0, 0.8
19
1.0
0.6, 1.4
26
1.9 **
1.2, 2.6
Cervix d
15
1.5
0.8, 2.2
47
2.4
1.7, 3.1
31
2.3
1.5, 3.1
None
953
97.2
96.2, 98.2
1859
96.5
95.8, 97.2
1296
95.7
94.9, 96.5
Unk c
4
0.4
0, 0.8
15
0.8
0.4, 1.2
23
1.7 **
1.0, 2.4
Colon d
15
1.5
0.8, 2.2
49
2.5
1.8, 3.2
45
3.3 **
2.3, 4.3
None
928
94.7
93.3, 96.1
1817
94.3
93.3, 95.3
1268
93.6
92.3, 94.9
Unk c
4
0.4
0, 0.8
17
0.9
0.5, 1.3
27
2.0 **
1.3, 2.7
Lung d
10
1.0
0.4, 1.6
34
1.8
1.2, 2.4
23
1.7
1.0, 2.4
None
958
97.8
96.9, 98.7
1865
96.8
96.0, 97.6
1304
96.2
95.2, 97.2
Unk c
4
0.4
0, 0.8
18
0.9
0.5, 1.3
25
1.9 **
1.2, 2.6
Thyroid d
5
0.5
0.1, 0.9
11
0.6
0.3, 0.9
5
0.4
0, 0.7
None
970
99.0
98.4, 99.6
1896
98.4
97.8, 99.0
1322
97.6
96.8, 98.4
Unk c
4
0.4
0, 0.8
18
0.9
0.5, 1.3
27
2.0 **
1.3, 2.7
Other d
54
5.5
4.1, 6.9
176
9.1
7.8, 10.4
161
11.9
10.2, 13.6
None
822
83.9
83.5, 84.3
1618
84.0
82.4, 85.6
1108
81.8
79.7, 83.9
Unk c
4
0.4
0, 0.8
12
0.6
0.3, 0.9
17
1.3 *
0.7, 1.9

a Women aged 20-20 years were excluded as too few reported a positive family history to generate stable estimates.
b
May not total 100% due to incomplete information on second-degree relatives.
c
Respondent did not know if her first-degree relatives had this cancer type.
d
Second-degree prevalence not reported due to incomplete information on aunts.
*?² trend: p<0.05; **?² , p<0.01 ; ***? ², p<0.001

back to report


TABLE 3: Age-adjusted prevalence of family history of cancer among female relatives by race of respondent, Cancer and Steroid Hormone study, 1980-1982a, N=4530

White (n=3782)
Black (n=462)
Other (n=286)
n
Prev (%)
95% CL
n
Prev (%)
95% CL
n
Prev (%)
95% CL
Breast
258
6.6
5.8, 7.4
22
4.7
2.8, 6.6
10
2.1 *
0.4, 3.8
547
14.9
13.8, 16.0
40
7.8 **
5.4, 10.2
15
7.1 ***
4.1, 10.1
None
2941
81.3
80.1, 82.5
396
87.4 ***
84.3, 90.4
256
91.0 ***
87.7, 94.3
Unk b
36
0.5
0.3, 0.7
4
0.7
0, 1.5
5
0.7
0, 1.7
Endometrium
130
2.4
1.9, 2.9
20
4.2
2.4, 6.0
8
1.4
0, 2.8
98
2.9
2.4, 3.4
12
2.8
1.3, 4.3
9
2.1
0.4, 3.8
None
3513
95.0
94.3, 95.7
427
93.2
90.9, 95.5
264
96.4
94.3, 98.6
Unk b
41
0.5
0.3, 0.7
3
0.6
0, 1.3
5
0.7
0, 1.7

a Age-adjusted to 1990 SEER U.S. standard population for mortality.
b
Respondent did not know if her first-degree relatives had this cancer type.
* versus white women: p<0.05; ** p<0.001; *** p<0.0001.

back to report


TABLE 4: Prevalence of family history of breast cancer among first-degree female relatives of controls from the Cancer and Steroid Hormone (CASH) study (1980-1982) and the Women’s Interview Study on Health (WISH) (1990-1992), Atlanta and Seattle

CASH
(1980 - 1982)
WISH
(1990 - 1992)
Cancer prevalence
n
Prev (%)
95% CL
OR a
n
Prev (%)
95% CL
OR a
Overall (%)
877
5.9
4.3, 7.5
1544
6.2
5.0, 7.4
Age-specific (%)
    20-29 years
63
0
NC
36
11.1
9.5, 12.7
2.06
    30-39 years
240
4.2
2.9, 5.5
1.00 b
430
5.8
4.6, 7.0
1.00 b
    40-49 years
343
7.3
5.6, 9.0
2.31 *
818
5.8
4.6, 7.0
0.98
    50-54 years
231
7.4
5.7, 9.1
2.26 *
260 c
7.3
6.0, 8.6
1.22
Race-specific (%)
    White
727
6.6
5.0, 8.2
1.00 b
1186
6.7
5.5, 7.9
1.00 b
    Black
123
1.6
0.8, 2.4
0.24 *
278
5.0
3.9, 6.1
0.72
    Other
27
7.4
5.7, 9.1
1.22
80
1.3
0.8, 1.9
0.18

a Separate multivariate models for each study were adjusted for age as a continuous variable and race.  Women aged 20-29 years were excluded from the CASH model.
b Referent group
c All women 50-54 years from the WISH study were from Atlanta.
* OR statistically significant.
NC – not calculated

back to report

Page last reviewed: November 1, 2001 (archived document)
Page last updated: December 11, 2007
Content Source: National Office of Public Health Genomics